> Details

Rüschoff, Josef; Schildhaus, Hans-Ulrich; Rüschoff, Jan Hendrik; Jöhrens, Korinna; Bocker Edmonston, Tina; Dietmaier, Wolfgang; Bläker, Hendrik; Baretton, Gustavo; Horst, David; Dietel, Manfred; Hartmann, Arndt; Klauschen, Frederick; Merkelbach-Bruse, Sabine; Stenzinger, Albrecht; Schöniger, Sandra; Tiemann, Markus; Weichert, Wilko; Büttner, Reinhard

Testing for deficient mismatch repair and microsatellite instability Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität : Eine fokussierte Aktualisierung. Englische Version A focused update

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Testing for deficient mismatch repair and microsatellite instability Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität : Eine fokussierte Aktualisierung. Englische Version A focused update : Eine fokussierte Aktualisierung. Englische Version
  • Contributor: Rüschoff, Josef; Schildhaus, Hans-Ulrich; Rüschoff, Jan Hendrik; Jöhrens, Korinna; Bocker Edmonston, Tina; Dietmaier, Wolfgang; Bläker, Hendrik; Baretton, Gustavo; Horst, David; Dietel, Manfred; Hartmann, Arndt; Klauschen, Frederick; Merkelbach-Bruse, Sabine; Stenzinger, Albrecht; Schöniger, Sandra; Tiemann, Markus; Weichert, Wilko; Büttner, Reinhard
  • imprint: Springer Science and Business Media LLC, 2023
  • Published in: Die Pathologie
  • Language: English
  • DOI: 10.1007/s00292-023-01208-2
  • ISSN: 2731-7196; 2731-7188
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Testing to detect mismatch repair deficiency (dMMR) and high-grade microsatellite instability (MSI-H) has become an integral part of the routine diagnostic workup for colorectal cancer (CRC). While MSI was initially considered to be a possible indicator of a hereditary disposition to cancer (Lynch syndrome, LS), today the prediction of the therapy response to immune checkpoint inhibitors (ICI) is in the foreground. Corresponding recommendations and testing algorithms are available for use in primary diagnosis (reviewed in: Rüschoff et al. 2021).</jats:p><jats:p>Given the increasing importance for routine use and the expanding indication spectrum of ICI therapies for non-CRCs, such as endometrial, small intestinal, gastric, and biliary tract cancers, an updated review of dMMR/MSI testing is presented. The focus is on the challenges in the assessment of immunohistochemical stains and the value of PCR-based procedures, considering the expanded ICI indication spectrum. A practice-oriented flowchart for everyday diagnostic decision-making is provided that considers new data on the frequency and type of discordances between MMR-IHC and MSI-PCR findings, and the possible role of Next Generation Sequencing in clarifying them. Reference is made to the significance of systematic quality assurance measures (e.g., QuIP MSI portal and multicenter proficiency testing), including regular continued training and education.</jats:p>